ThermoBreast is a major ambitious European initiative. Its unique international clinical study will allow health policy makers to adopt better patient screening and monitoring programmes by including ThermoBreast as a supplementary imaging modality, resulting in a reduced rate of false negatives and overdiagnosis of other modalities in population-based screenings. As it will not be prone to human subjectivity and due to its seamless screening and automated analysis, ThermoBreast will also provide physicians with instant, unbiased answers to support their decision-making. In hospital settings, the ThermoBreast device will be located in a controlled-temperature room and operated by certified nurses and technicians. Trained staff will be conducting the whole process of the examination, adjusting it to the patient characteristics and ensuring the implementation of screening steps. Upon installation, it can screen 17 women per day, ultimately lessening the physical and mental strain of breast cancer patients and healthcare providers.